THE TGA has not approved a product referred to as 'Haytox', which is being promoted as a treatment for nasal allergies.
The TGA stated it has not evaluated this product and, therefore, warns consumers that it cannot guarantee the quality, safety or efficacy of the product.
Consumers should be made aware of the risk of serious side effects when accessing medicines for an unapproved use.
The TGA reminds healthcare professionals that they must not mislead patients as to a product's safety or efficacy.
It appears that 'Haytox' may contain the botulinum toxin or botox, TGA added.
It is unlawful to advertise therapeutic goods that are not on the ARTG to the public, or in a way that is inconsistent with the product's entry in the register, such as a different medicinal use.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Oct 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Oct 23
